AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 ...

AbbVie has entered a collaboration with Gedeon Richter (Richter) to develop new treatments for neuropsychiatric conditions.

Argent Capital Management LLC reduced its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 96.3% in the 3rd quarter, ...

AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.

AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric ...

Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...

In the closing of the recent trading day, AbbVie (ABBV) stood at $189.65, denoting a +0.94% change from the preceding trading day.

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Vyalev, also known as Produodopa, has been approved in 35 countries, with more than 4200 patients having started treatment.

Related: Analyst revises AbbVie stock price target on drug-sale estimates Sales eroded, however, as Humira faced competition ...

Failed to import article template. Reason: Failed to fetch dynamically imported module: ...

伊利诺伊州北芝加哥 - 艾伯维公司（纽约证券交易所代码：ABBV）和Gedeon Richter Plc.宣布达成协议，共同发现和开发治疗神经精神疾病的新疗法。这项合作建立在近20年的合作伙伴关系基础之上，该合作关系已经产生了中枢神经系统疗法，包括cariprazine（VRAYLAR® / REAGILA®）和研究中的药物ABBV-932。